Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTIMICROBIAL PRESERVATIVE RESTRICTED USE IN SINGLE-DOSE PARENTERALS

Executive Summary

ANTIMICROBIAL PRESERVATIVE RESTRICTED USE IN SINGLE-DOSE PARENTERALS is under consideration by FDA, the agency announced in a May 15 Federal Register notice. FDA said it is "considering whether to propose to prohibit the use of benzyl alcohol in single-dose products, such as heparin solutions, which are frequently administered to newborn infants," or whether "to propose to prohibit the use of any antimicrobial preservative in single-dose containers of parenteral products frequently administered to newborn infants." With respect to the use of preservatives in multiple-dose parenteral products, FDA said it is considering requiring a label warning for either all such products, or for those products containing benzyl alcohol which are frequently administered to newborn infants, or for all multiple-dose parenterals containing any antimicrobial preservative which are frequently administered to newborns. "The warning would state that caution should be used in the administration of these drugs to newborn infants and individuals with impaired liver function," FDA said. The agency explained that it was considering such actions "because of reports linking the use of parenteral drug products containing an antimicrobial preservative, particularly bacteriostatic water for injection and bacteriostatic sodium chloride injection preserved with benzyl alcohol, to morbidity and mortality among low-weight newborn infants." FDA said the syndrome, which is "possibly linked" to the products, "is characterized by central nervous system depression, metabolic acidosis, and gasping respirations" and can "lead to serious renal and other system failures, hypotension, and less frequently, to intracranial hemorrhage and death." The agency noted that it is theorized "that the immature liver of the low-weight, premature infant is incapable of properly metabolizing and excreting benzyl alcohol and its metabolites." In requesting comments on the possible agency proposals, FDA also requested information "concerning the need for a general warning statement or other actions applicable to parenteral drug products containing any substance that could be considered a preservative intended for newborn infants, other special patient populations, or for all patients." For instance, FDA said such additives as antioxidants and stabilizers, while generally considered nontoxic, have been associated with toxicity reports from time to time.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel